DE69804974T2 - Opioid-konjugate mit endogenen trägerproteinen - Google Patents
Opioid-konjugate mit endogenen trägerproteinenInfo
- Publication number
- DE69804974T2 DE69804974T2 DE69804974T DE69804974T DE69804974T2 DE 69804974 T2 DE69804974 T2 DE 69804974T2 DE 69804974 T DE69804974 T DE 69804974T DE 69804974 T DE69804974 T DE 69804974T DE 69804974 T2 DE69804974 T2 DE 69804974T2
- Authority
- DE
- Germany
- Prior art keywords
- patient
- conjugates
- antinociceptive
- conjugate
- vivo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6470597P | 1997-11-07 | 1997-11-07 | |
PCT/US1998/023704 WO1999024074A2 (en) | 1997-11-07 | 1998-11-06 | Novel conjugates of opioids and endogenous carriers |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69804974D1 DE69804974D1 (de) | 2002-05-23 |
DE69804974T2 true DE69804974T2 (de) | 2002-11-07 |
Family
ID=22057753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69804974T Expired - Lifetime DE69804974T2 (de) | 1997-11-07 | 1998-11-06 | Opioid-konjugate mit endogenen trägerproteinen |
DE69812727T Expired - Lifetime DE69812727D1 (de) | 1997-11-07 | 1998-11-06 | Opioid-konjugate mit endogenen Trägerproteinen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69812727T Expired - Lifetime DE69812727D1 (de) | 1997-11-07 | 1998-11-06 | Opioid-konjugate mit endogenen Trägerproteinen |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP1028971A2 (de) |
JP (2) | JP2001522817A (de) |
AT (2) | ATE216402T1 (de) |
AU (3) | AU1519799A (de) |
CA (2) | CA2309205A1 (de) |
DE (2) | DE69804974T2 (de) |
ES (1) | ES2173641T3 (de) |
IL (1) | IL135835A0 (de) |
WO (3) | WO1999024074A2 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6437092B1 (en) | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
IL133053A0 (en) * | 1998-03-23 | 2001-03-19 | Conjuchem Inc | Local delivery of long lasting therapeutic agents |
AU773891C (en) | 1998-10-23 | 2005-02-17 | Kirin-Amgen Inc. | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
JP4209086B2 (ja) * | 1999-05-17 | 2009-01-14 | コンジュケム バイオテクノロジーズ インコーポレイテッド | 長期持続性抗新脈管形成ペプチド |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US7144854B1 (en) | 1999-09-10 | 2006-12-05 | Conjuchem, Inc. | Long lasting anti-angiogenic peptides |
ES2257298T3 (es) * | 1999-05-17 | 2006-08-01 | Conjuchem, Inc. | Proteccion de peptidos terapeuticos endogenos contra la actividad de la peptidasa a traves de la conjugacion con componentes sanguineos. |
PT1180121E (pt) | 1999-05-17 | 2004-03-31 | Conjuchem Inc | Peptidos insulinotropicos de longa duracao |
EP1264840B1 (de) | 1999-05-17 | 2009-09-23 | ConjuChem Biotechnologies Inc. | Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
EA006484B1 (ru) | 2001-02-02 | 2005-12-29 | Конджачем, Инк. | Долгоживущие производные рилизинг-фактора гормона роста |
JP4280070B2 (ja) | 2001-02-16 | 2009-06-17 | コンジュケム バイオテクノロジーズ インコーポレイテッド | 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2) |
ES2277173T3 (es) | 2001-05-31 | 2007-07-01 | Conjuchem Biotechnologies Inc. | Inhibidores peptidos de fusion de larga vida contra infecciones por vih. |
ATE466953T1 (de) | 2003-01-17 | 2010-05-15 | Advanced Proteome Therapeutics | Verfahren zur identifizierung aktivierter polymer-komplexe zur sekundären stellen-spezifischen modifikation von protein ziel-gruppen. |
DE602005022239D1 (de) | 2004-04-23 | 2010-08-19 | Conjuchem Biotechnologies Inc | Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten |
WO2006010057A2 (en) | 2004-07-08 | 2006-01-26 | Amgen Inc. | Therapeutic peptides |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2114437A2 (de) | 2006-10-16 | 2009-11-11 | ConjuChem Biotechnologies Inc. | Modifizierte peptide mit corticotropinfreisetzungsfaktor und verwendungen davon |
GB201204868D0 (en) | 2012-03-20 | 2012-05-02 | San Raffaele Centro Fond | Peptides |
EP3201166A4 (de) * | 2014-07-18 | 2018-06-27 | Biocogent, LLC | Zusammensetzungen und verfahren mit salicylaten und polysalicylaten |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59138958A (ja) * | 1983-01-31 | 1984-08-09 | Mitsubishi Chem Ind Ltd | 抗血清 |
US4784955A (en) * | 1984-09-21 | 1988-11-15 | Miles Inc. | Immunogen conjugates and the use thereof in a dihydropyridine assay |
IE901736L (en) * | 1989-05-17 | 1990-11-17 | Fuller H B Licensing Financ | Polypeptide-antibody conjugate for inhibiting cell adhesion |
DK608589D0 (da) * | 1989-12-01 | 1989-12-01 | Holm Arne | Kemisk fremgangsmaade |
US5292362A (en) * | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
JPH04364200A (ja) * | 1991-06-10 | 1992-12-16 | Unitika Ltd | 細胞接着性アルブミン |
US5399671A (en) * | 1992-11-18 | 1995-03-21 | Kluger; Ronald | Specifically crosslinked hemoglobin with free functionality |
US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
-
1998
- 1998-11-06 DE DE69804974T patent/DE69804974T2/de not_active Expired - Lifetime
- 1998-11-06 IL IL13583598A patent/IL135835A0/xx unknown
- 1998-11-06 JP JP2000520159A patent/JP2001522817A/ja active Pending
- 1998-11-06 WO PCT/US1998/023704 patent/WO1999024074A2/en active IP Right Grant
- 1998-11-06 DE DE69812727T patent/DE69812727D1/de not_active Expired - Lifetime
- 1998-11-06 CA CA002309205A patent/CA2309205A1/en not_active Abandoned
- 1998-11-06 ES ES98956656T patent/ES2173641T3/es not_active Expired - Lifetime
- 1998-11-06 AT AT98956656T patent/ATE216402T1/de not_active IP Right Cessation
- 1998-11-06 EP EP98957648A patent/EP1028971A2/de not_active Withdrawn
- 1998-11-06 AT AT01121557T patent/ATE235513T1/de not_active IP Right Cessation
- 1998-11-06 EP EP98956656A patent/EP1007561B1/de not_active Expired - Lifetime
- 1998-11-06 CA CA002301799A patent/CA2301799C/en not_active Expired - Fee Related
- 1998-11-06 WO PCT/US1998/023702 patent/WO1999024462A2/en not_active Application Discontinuation
- 1998-11-06 AU AU15197/99A patent/AU1519799A/en not_active Abandoned
- 1998-11-06 JP JP2000520470A patent/JP2001522863A/ja active Pending
- 1998-11-06 AU AU13127/99A patent/AU750387B2/en not_active Ceased
- 1998-11-06 WO PCT/US1998/023706 patent/WO1999024076A2/en active Application Filing
- 1998-11-06 AU AU13856/99A patent/AU1385699A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69804974D1 (de) | 2002-05-23 |
JP2001522817A (ja) | 2001-11-20 |
AU1312799A (en) | 1999-05-31 |
EP1007561A2 (de) | 2000-06-14 |
CA2301799A1 (en) | 1999-05-20 |
WO1999024462A2 (en) | 1999-05-20 |
CA2301799C (en) | 2007-08-07 |
ES2173641T3 (es) | 2002-10-16 |
AU750387B2 (en) | 2002-07-18 |
WO1999024076A2 (en) | 1999-05-20 |
WO1999024074A2 (en) | 1999-05-20 |
WO1999024076A9 (en) | 2000-06-08 |
AU1385699A (en) | 1999-05-31 |
WO1999024074A3 (en) | 1999-08-19 |
CA2309205A1 (en) | 1999-05-20 |
EP1007561B1 (de) | 2002-04-17 |
AU1519799A (en) | 1999-05-31 |
DE69812727D1 (de) | 2003-04-30 |
EP1028971A2 (de) | 2000-08-23 |
ATE235513T1 (de) | 2003-04-15 |
WO1999024462A3 (en) | 1999-08-26 |
WO1999024076A3 (en) | 1999-08-19 |
JP2001522863A (ja) | 2001-11-20 |
ATE216402T1 (de) | 2002-05-15 |
IL135835A0 (en) | 2001-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69804974T2 (de) | Opioid-konjugate mit endogenen trägerproteinen | |
Ringsdorf | Structure and properties of pharmacologically active polymers | |
CA2064689A1 (en) | Stabilized protein or peptide conjugates | |
NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
AU2259392A (en) | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology | |
EP0329184A3 (de) | Antimere und antimere Konjugation | |
WO1999048536A3 (en) | Delivery of long lasting therapeutic agents by forming covalent attachments in vivo | |
BR0016339A (pt) | Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto | |
Poznansky et al. | Insulin: carrier potential for enzyme and drug therapy | |
WO1999056723A3 (en) | Hemoglobine-haptoglobin complexes for targeted drug delivery | |
WO2001060412A3 (en) | Modification of biopolymers for improved drug delivery | |
IL161670A0 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
US5411943A (en) | Hepatoma treatment with somatostatin analogs | |
AU2503900A (en) | Sulfated phosphatidylinositols, their preparation and use | |
Basu et al. | Enhanced intracellular delivery of doxorubicin by scavenger receptor‐mediated endocytosis for preferential killing of histiocytic lymphoma cells in culture | |
IL117564A (en) | Pharmaceutical and diagnostic compositions containing lysine derivatives | |
CA2326720A1 (en) | Hemoglobin-haptoglobin complexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: CONJUCHEM BIOTECHNOLOGIES INC., MONTREAL, QUEBEC, |